Navigation Links
Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
Date:10/25/2011

erosis, Product Pipeline, 2011 169

Table 115: CNS Disorder Therapeutic Market, Parkinson's Disease, Product Pipeline, 2011 175

Table 116: CNS Disorder Therapeutic Market, Schizophrenia, Product Pipeline, 2011 182

Table 117: CNS Disorder Therapeutic Market, Global, M&A Deals ($m), 2010-2011 206

Table 118: CNS Disorder Therapeutic Market, Global, Announced M&A Deals ($m), 2010-2011 207

Table 119: CNS Disorder Therapeutic Market, Global, Licensing Deals ($m), 2010-2011 212

Table 120: CNS Disorder Therapeutic Market, Co-developments, 2010-2011 218

1.2 List of Figures

Figure 1: CNS Disorder Therapeutic Market, Global, Revenue Share by Indication (%), 2010 16

Figure 2: CNS Disorder Therapeutic Market, Global, Revenue Forecast ($bn), 2002-2017 17

Figure 3: CNS Disorder Therapeutic Market, Global, Generic Share (%), 2010 and 2017 18

Figure 4: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2002-2017 19

Figure 5: CNS Disorder Therapeutic Market, Revenue by Geography (%),2010 25

Figure 6: CNS Disorder Therapeutic Market, The US, Revenue Forecast ($m), 2002-2017 26

Figure 7: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2002-2017 27

Figure 8: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue Forecast ($m), 2002-2017 28

Figure 9: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 30

Figure 10: CNS Disorder Therapeutic Market, Japan, Revenue Forecast ($m), 2002-2017 31

Figure 11: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2002-2017 32

Figure 12: CNS Disorder Therapeutic Market, Alzheimer's Disease Treatment Algorithm 34

Figure 13: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Revenue Forecast ($bn), 2002-2017 35

Figure 14: CNS Disorder Therapeutics Market, Alz
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. Bioness Inc. Receives FDA Clearance and CE Mark for Its NESS H200 Wireless System for Hand Paralysis as a Result of Stroke and Other Central Nervous System Disorders
2. South and Central America Cardiovascular Devices Market Outlook to 2017
3. Carolinas HealthCare System (CHS) Contributes to First Childrens Burn Hospital in Central America
4. Pharmaceutical Contract Manufacturing and API Sourcing in Central Europe and the Balkan States 2011
5. United Seating & Mobility Reaches Agreement to Acquire Central Kentucky Mobility
6. Reportlinker Adds South and Central America Dental Devices Market Outlook to 2017
7. Reportlinker Adds South and Central America Drug Delivery Devices Market Outlook to 2017
8. Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
9. Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
10. Reportlinker Adds Drug Delivery Devices Market Outlook in Russian Federation to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
11. Reportlinker Adds Drug Delivery Devices Market Outlook in China to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014 WHEN: Wednesday, October 29, ... registration available at: http://bit.ly/1yStiU9 SPEAKERS: ... and Visionary Innovation Research Group Senior Research ... self-assembling materials, nanobots and flexible electronics are ... transform our lives in the coming decades. ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)...  Luoxis Diagnostics, Inc., a subsidiary of Ampio ... its academic collaborators will present several peer-reviewed posters ... novel RedoxSYS Diagnostic System, a first-in-class platform that ... response to injury or illness.  A poster demonstrating ... marker will be presented by Christopher V. ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... A of Trial Assessing Regimen of ... TUSTIN, Calif., Oct. 7 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... for the treatment of cancer and,hepatitis C virus (HCV) ... first stage of a Phase II trial of bavituximab ...
... TOKYO and CHIPPENHAM, England, October 7 ,Sosei ... and Vectura,Group plc ("Vectura"; LSE: VEC), announce ... efficacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data ...
Cached Medicine Technology:Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... of conventional in vitro fertilization (IVF) -- the incubation of ... in a device inside the vagina, new research suggests. ... device, called an INVOcell, might sharply cut costs for pricey ... technology more accessible to those who don,t live near big-city ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay News) -- ... NBC News in Liberia has cleared the virus from ... Medical Center in Omaha, where he had been treated for the ... confirmed by the U.S. Centers for Disease Control and Prevention found ... NBC News reported Tuesday night. "Recovering from Ebola is ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
(Date:10/20/2014)... 20, 2014 Women’s health specialist, Dr. ... & Gynecology of Columbus, Inc., A Division of MaternOhio ... to more than 100,000 patients annually. Dr. Murphy will ... and stages of a women’s life. She is accepting ... in Westerville and Dublin. , Dr. Murphy offers a ...
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... people suffering from tension-headaches, acupuncture may be the right ... BMJ said that acupuncture can reduce the incidence of ... the gold standard of clinical trials - researchers in ... tension headache into three groups. ,Over an ...
... Streptococcus suis and the first case was reported in June// ... mostly farmers and butchers, who handled infected pigs or people ... China, the infected pigs are thought to have come from ... 70 areas in and around the two cities of Ziyang ...
... new study says//. ,Phillip Marucha, and his colleagues ... study of laboratory mice, found that psychological stress, brought ... more than 45 percent, reports science portal eurekalert.org. ... for the slow recovery, it said. ,"The ...
... of Michigan Cardiovascular Center had presented new findings// ... that can cure inflammations in patients who had ... ,In a recent study the scientists had found ... several weeks after transplant surgery prevented the development ...
... be unconscious and happen even when people are not aware ... July 28, 2005 issue of Nature. ,Researchers from University ... Diego Veterans Affairs Health System had undertaken the study to ... formed even when they are actually not aware of doing ...
... neurodegenerative and ultimately fatal disease// that slowly destroys the ... the ability to take care of themselves and require ... ,Based on findings of a recent study researchers say ... help slow the progression of Alzheimer's disease by reducing ...
Cached Medicine News:Health News:Acupuncture May Be An Effective Treatment Against Tension-Headaches 2Health News:Research Shows Carbon Monoxide Prevents Inflammations 2Health News:Habit Memory May Enhance Learning In People 2
... Peel PRESTIGE system was designed with advanced ... of the most demanding skin care practice. ... the Parisian Peel PRESTIGE machine is designed ... to offer maximum versatility and full abrasion ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
Latex agglutination inhibition slide test for the qualitative detection of hCG in urine....
Test for the quantitative determination of antideoxyribonuclease-B (ADNase-B) in serum....
Medicine Products: